118 related articles for article (PubMed ID: 11271495)
61. Proteome of H-411E (liver) cells exposed to insulin and tumor necrosis factor-alpha: analysis of proteins involved in insulin resistance.
Solomon SS; Buss N; Shull J; Monnier S; Majumdar G; Wu J; Gerling IC
J Lab Clin Med; 2005 May; 145(5):275-83. PubMed ID: 15902099
[TBL] [Abstract][Full Text] [Related]
62. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons.
Park DS; Farinelli SE; Greene LA
J Biol Chem; 1996 Apr; 271(14):8161-9. PubMed ID: 8626506
[TBL] [Abstract][Full Text] [Related]
63. Protein profile of the HeLa cell line.
Fountoulakis M; Tsangaris G; Oh JE; Maris A; Lubec G
J Chromatogr A; 2004 Jun; 1038(1-2):247-65. PubMed ID: 15233540
[TBL] [Abstract][Full Text] [Related]
64. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
65. Cell death mediated by alloreactive cytotoxic T cells via the granule exocytosis or the Fas pathway is independent of p34cdc2 kinase: Fas dependent killing of cells arrested in the cell cycle.
Waring P; Müllbacher A
Immunol Cell Biol; 2001 Jun; 79(3):264-73. PubMed ID: 11380680
[TBL] [Abstract][Full Text] [Related]
66. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
[TBL] [Abstract][Full Text] [Related]
67. Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine.
Novakova O; Liskova B; Vystrcilova J; Suchankova T; Vrana O; Starha P; Travnicek Z; Brabec V
Eur J Med Chem; 2014 May; 78():54-64. PubMed ID: 24675180
[TBL] [Abstract][Full Text] [Related]
68. Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.
Knillová J; Bouchal J; Hlobilková A; Strnad M; Kolár Z
Neoplasma; 2004; 51(5):358-67. PubMed ID: 15640940
[TBL] [Abstract][Full Text] [Related]
69. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
70. Cyclin-dependent kinase (CDK) inhibitor olomoucine enhances gamma-irradiation-induced apoptosis and cell cycle arrest in Raji cells.
Boutis A; Papazisis K; Pistevou-Gompaki K; Lambropoulos A; Sofroniadis I; Papageorgiou A; Destouni E; Kortsaris A
Anticancer Res; 2006; 26(5A):3493-8. PubMed ID: 17094472
[TBL] [Abstract][Full Text] [Related]
71. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine.
Yakisich JS; Sidén A; Idoyaga Vargas V; Eneroth P; Cruz M
Biochem Biophys Res Commun; 1998 Feb; 243(3):674-7. PubMed ID: 9500988
[TBL] [Abstract][Full Text] [Related]
72. Matrix assisted laser desorption/ionization-time of flight-mass spectrometry analysis of proteins detected by anti-phosphotyrosine antibody on two-dimensional-gels of fibrolast cell lysates after tumor necrosis factor-alpha stimulation.
Yanagida M; Miura Y; Yagasaki K; Taoka M; Isobe T; Takahashi N
Electrophoresis; 2000 May; 21(9):1890-8. PubMed ID: 10870974
[TBL] [Abstract][Full Text] [Related]
73. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.
Lu K; Shih C; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(4):293-304. PubMed ID: 11052627
[TBL] [Abstract][Full Text] [Related]
74. The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors.
Peñuelas S; Alemany C; Noé V; Ciudad CJ
Eur J Biochem; 2003 Dec; 270(24):4809-22. PubMed ID: 14653808
[TBL] [Abstract][Full Text] [Related]
75. Structural basis for chemical inhibition of CDK2.
Kim SH; Schulze-Gahmen U; Brandsen J; de Azevedo Júnior WF
Prog Cell Cycle Res; 1996; 2():137-45. PubMed ID: 9552391
[TBL] [Abstract][Full Text] [Related]
76. 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.
Imbach P; Capraro HG; Furet P; Mett H; Meyer T; Zimmermann J
Bioorg Med Chem Lett; 1999 Jan; 9(1):91-6. PubMed ID: 9990463
[TBL] [Abstract][Full Text] [Related]
77. Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs.
Ribas J; Boix J
Exp Cell Res; 2004 Apr; 295(1):9-24. PubMed ID: 15051486
[TBL] [Abstract][Full Text] [Related]
78. ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells.
Zhang W; Lee JC; Kumar S; Gowen M
J Bone Miner Res; 1999 Apr; 14(4):528-35. PubMed ID: 10234573
[TBL] [Abstract][Full Text] [Related]
79. Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells.
Jin YH; Yoo KJ; Lee YH; Lee SK
J Biol Chem; 2000 Sep; 275(39):30256-63. PubMed ID: 10884382
[TBL] [Abstract][Full Text] [Related]
80. Correlation between semaphorin3A-induced facilitation of axonal transport and local activation of a translation initiation factor eukaryotic translation initiation factor 4E.
Li C; Sasaki Y; Takei K; Yamamoto H; Shouji M; Sugiyama Y; Kawakami T; Nakamura F; Yagi T; Ohshima T; Goshima Y
J Neurosci; 2004 Jul; 24(27):6161-70. PubMed ID: 15240808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
